ArticleFrontiers in immunology2026
B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Occult breast cancer (OBC) presents with axillary lymph node (ALN) metastases without detectable primary tumor (PT) yet exhibits paradoxically favorable prognosis compared to non-occult breast cancer (non-OBC). We aimed to elucidate mechanisms underlying PT clearance by integrating multi-omics approaches to characterize the unique immune landscape. Methods: Survival outcomes were validated using the Surveillance, Epidemiology, and End Results (SEER) database (n=12,162) with propensity score matching (PSM). Molecular features were characterized via quantitative proteomics, while immune landscapes were assessed using bulk transcriptomics. Single-cell RNA sequencing (scRNA-seq) and CellChat analysis dissected cellular heterogeneity and intercellular communication within tumor microenvironment. Results: Survival analysis confirmed OBC patients have survival comparable to T1N+M0 but significantly better than T2-3N+M0 breast cancer (BC) patients. Proteomic profiling identified B cell-related pathway upregulation in OBC lymph nodes (LN). Transcriptomics revealed enriched B cell infiltration in T1 tumors correlating with improved survival. scRNA-seq further demonstrated that B cells in T1 tumors act as central hubs in intercellular communication. These cells orchestrate a robust anti-tumor response via multi-faceted secretory signals (e.g., tumor necrosis factor, TNF; B-cell activating factor, BAFF) and contact-dependent interactions (e.g., CD40; major histocompatibility complex, MHC), effectively recruiting and activating immune effectors. Conclusion: Our findings suggest that B cell-mediated immune surveillance may be a key mechanism contributing to the clearance of PT in OBC. These exploratory results underscore the potential of B cells as prognostic biomarkers and therapeutic targets in BC, pending functional validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.